922 results on '"Straus, David"'
Search Results
2. CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas
3. Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP
4. Retrospective characterization of nodal marginal zone lymphoma
5. TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
6. Growth, body composition, and survival of juvenile white bass (Morone chrysops) when dietary fish meal is partially or totally replaced by soybean meal, poultry by-product meal, an all-plant protein blend or a commercial plant-animal protein blend
7. The Influence of South Pacific Convergence Zone Heating on the South Pacific Subtropical Anticyclone
8. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
9. Involved-site radiotherapy for Helicobacter pylori–independent gastric MALT lymphoma: 26 years of experience with 178 patients
10. Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue
11. Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era
12. Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies
13. Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma
14. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study
15. Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
16. Utilization of clinical genetic counseling among childhood and young adult cancer survivors in a registry trial
17. A modelling framework for a better understanding of the tropically-forced component of the Indian monsoon variability
18. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma
19. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma
20. Intrinsic predictability limits arising from Indian Ocean Madden–Julian oscillation (MJO) heating: effects on tropical and extratropical teleconnections
21. Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1
22. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET
23. Trauma deserts: distance from a trauma center, transport times, and mortality from gunshot wounds in Chicago.
24. Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good long-term outcomes
25. TP53mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
26. Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
27. The Treatment of Non-Hodgkin's Lymphomas
28. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
29. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups
30. Molecular Basis of T Cell Inactivation by CTLA-4
31. Takashi Yura: pioneer, visionary scientist, friend
32. Peracetic acid is a suitable disinfectant for recirculating fish-microalgae integrated multi-trophic aquaculture systems
33. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
34. The Cape Town “Day Zero” drought and Hadley cell expansion
35. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse
36. Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting
37. Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
38. Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing
39. Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2
40. Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)
41. Characterization of a Large Cohort of Patients with Nodal Marginal Zone Lymphoma Shows Prolonged Survival, Time-to-Treatment, and Time-to-Transformation
42. T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma
43. P009: Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1
44. Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay
45. Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase 2 Study of an MRD-driven Approach
46. Targeting Mast Cells in Allergic Disease: Current Therapies and Drug Repurposing
47. Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach
48. Model Estimates of Land-Driven Predictability in a Changing Climate from CCSM4
49. The Indian Monsoon Circulation Response to El Niño Diabatic Heating
50. The Impact of Land Surface and Atmospheric Initialization on Seasonal Forecasts with CCSM
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.